Anti-VEGF Therapy and the Retina: An Update.
Anti-VEGF Therapy and the Retina: An Update.
复制标题
DOI：
10.1155/2015/627674
复制
发表时间：
2015
影响因子：
1.9
通讯作者：
Pasu S
中科院分区：
文献类型：
--
作者：
Tah V;Orlans HO;Hyer J;Casswell E;Din N;Sri Shanmuganathan V;Ramskold L;Pasu S
眼血管生成和黄斑水肿是全世界范围内导致视力丧失的主要原因。异常新生血管形成可能继发于许多疾病过程，可导致视力下降，原因是水肿、出血和疤痕形成。抗血管内皮生长因子(抗血管内皮生长因子)药物的发展使视网膜血管新生疾病的治疗发生了革命性的变化。这些药物现在通常用于治疗多种眼部疾病，包括脉络膜新生血管、糖尿病黄斑水肿和视网膜静脉阻塞等。在这篇文章中，我们将探讨目前抗血管内皮生长因子在各种视网膜疾病中的使用情况，以及这些药物对患者视力结局的影响。
Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring. The development of antivascular endothelial growth factor (anti-VEGF) agents has revolutionised the treatment of retinal vasogenic conditions. These drugs are now commonly employed for the treatment of a plethora of ocular pathologies including choroidal neovascularisation, diabetic macular oedema, and retinal vein occlusion to name a few. In this paper, we will explore the current use of anti-VEGF in a variety of retinal diseases and the impact that these medications have had on visual outcome for patients.